Publicacións en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (16)

2024

  1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  2. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3

  3. Regional and intratumoral adoptive T-cell therapy

    Immuno-Oncology and Technology, Vol. 24

  4. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

2023

  1. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

    Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60

2022

  1. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

    The Lancet Oncology, Vol. 23, Núm. 1, pp. 77-90

2021

  1. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 9

2020

  1. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

    Journal of Hepatology, Vol. 73, Núm. 6, pp. 1460-1469

2019

  1. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis

    Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4663-4673

2018

  1. Introducing a new series: Immunotherapy facts and hopes

    Clinical Cancer Research

  2. Perspectives in immunotherapy: Meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

2017

  1. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody

    Clinical Cancer Research, Vol. 23, Núm. 8, pp. 1929-1936

2016

  1. Immunodynamics: A cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

    Journal for ImmunoTherapy of Cancer, Vol. 4, Núm. 1

2014

  1. Classification of current anticancer immunotherapies

    Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508

2013

  1. Agonist antibodies to TNFR molecules that costimulate T and NK cells

    Clinical Cancer Research, Vol. 19, Núm. 5, pp. 1044-1053

2011

  1. Defining the critical hurdles in cancer immunotherapy

    Journal of Translational Medicine